Results 11 to 20 of about 14,657 (135)
Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial
Journal of Orthopedics, Traumatology and Rehabilitation, 2023 Context: Osteoporosis remains a significant public health problem in many parts of the world, including India. The efficacy of oral bisphosphonates is lower because of poor compliance.
Asif Hussain +5 more
doaj +1 more source
PLoS ONE, 2012 BackgroundZoledronic acid is widely used as adjuvant chemotherapy for the treatment of breast cancer. However, previous trials reported inconsistent findings regarding their clinical efficacy and safety.
Wei-Wei Huang +4 more
doaj +1 more source
Jurnal Manajemen dan Pelayanan Farmasi, 2020 Zoledronic acid and ibandronic acid are listed in the Indonesian national formulary to prevent skeletal-related events (SRE) in patients diagnosed with bone metastasis in multiple myeloma (MM), with limited evidence to compare their effectiveness.
Nutrisia Aquariushinta Sayuti +3 more
doaj +1 more source
Frontiers in Pharmacology, 2020 ObjectiveThis study aims to estimate the cost-effectiveness of yearly intravenous zoledronic acid treatment versus weekly oral alendronate for postmenopausal osteoporotic women in China.MethodsWe used a Markov microsimulation model to compare the cost ...
Ruxu You +8 more
doaj +1 more source
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
JBMR Plus, 2020 Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patients exhibit a variable sensitivity to zoledronic acid; the underlying explanation for this remains unclear.
Anaïs M J Møller +5 more
doaj +1 more source
Denosumab versus zoledronic acid in elderly patients after hip fracture
Journal of Orthopaedic Surgery, 2022 Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis.
Seung-Ju Kim, Ji Woon Kim, Dong-Woo Lee
doaj +1 more source
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
Journal of Medical Case Reports, 2011 Introduction Zoledronic acid is a highly effective treatment in Paget's disease for persistent bone pain and prevention of further progression of the disease. The commonest electrolyte abnormality is hypocalcemia. To the best of our knowledge this is the
Naysmith Morag +2 more
doaj +1 more source
Zoledronic acid inhibits the growth of leukemic MLL-AF9 transformed hematopoietic cells
Heliyon, 2020 A leukemic in vitro model produced by transducing Cord Blood derived-hematopoietic CD34+ cells with the MLL-AF9 translocation resulting in the oncogenic fusion protein, is used to assess for sensitivity to Zoledronic acid.
Emanuela Chiarella +9 more
doaj +1 more source
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
Journal of Bone Oncology, 2014 Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases.
Maria Wilke +8 more
doaj +1 more source
Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells. [PDF]
PLoS ONE, 2012 BACKGROUND: Zoledronic acid, one of the most potent nitrogen-containing biphosphonates, has been demonstrated to have direct anti-tumor and anti-metastatic properties in breast cancer in vitro and in vivo.
Yu-Guang Ma +10 more
doaj +1 more source